Jefferies raised the firm’s price target on Pacira to $18 from $15 and keeps a Buy rating on the shares. After having hosted management meetings that the firm says “continue to support our base case expectation” that the company will not face generic competition in 2025, Jefferies views consensus revenue forecasts next year as “overly punitive.” While the legal situation is expected to remain an overhang, the company has other patents at play and the firm believes the potential for generic entry “could still be years away,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Largest borrow rate increases among liquid names
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Warner Bros. downgraded, Starbucks upgraded: Wall Street’s top analyst calls
- Truist double downgrades Pacira on imminent generic Exparel launch